Clinical Trial

A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient

Name: A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient — clinical trial record (NCT07649395)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed

View on ClinicalTrials.gov →

Summary

To explore the early intervention timing of recombinant human thrombopoietin (rhTPO) for cancer treatment-induced thrombocytopenia (CTIT) in cervical squamous cell carcinoma (CSCC) patients during concurrent chemoradiotherapy.

Trial Details

NCT Number	NCT07649395
Lead Sponsor	Mei Feng
Conditions	Cervical Squamous Cell Carcinoma
Enrollment	75 participants
Start Date	2021-02-01
Primary Completion	2024-06-30 (estimated)
Study Completion	2024-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-16